Navigation Links
Congresso ESH 2013, dallo studio SEVITENSION nuove evidenze sull'efficacia della combinazione fissa olmesartan/amlodipina vs. perindopril/amlodipina nel controllo della pressione arteriosa centrale
Date:6/25/2013

MILANO, June 25, 2013 /PRNewswire/ --

Nel corso del 23° Congresso della Società Europea di Ipertensione sono stati presentati gli ultimi dati dello studio SEVITENSION, che mostrano l'efficacia superiore della combinazione fissa olmesartan/amlodipina rispetto alla combinazione perindopril/amlodipina nel controllo della pressione arteriosa centrale. SEVITENSION prende le mosse dai risultati del precedente studio CAFÉ-Conduit Artery Function Evaluation (parte dello studio ASCOT), che aveva mostrato come i trattamenti in combinazione fissa abbiano effetti differenti sulla pressione arteriosa centrale.

"Queste evidenze - ha dichiarato Luis Ruilope, direttore dell'Unità Antipertensiva dell'Ospedale 12 Ottobre di Madrid e coordinatore dello studio Sevitension - potrebbero spiegare la differenza dei risultati clinici fra i due gruppi dello studio ASCOT e fornire utili indicazioni per aiutare i medici a scegliere la miglior opzione di trattamento per gestire in maniera più efficace e conveniente l'ipertensione, proteggendo i pazienti dal rischio cardiovascolare. L'ambizione è quella di raggiungere l'obiettivo di controllare adeguatamente la pressione arteriosa nel 70% dei pazienti entro il 2015".

Gli inibitori dell'enzima di conversione dell'angiotensina (ACE-I) agiscono bloccando l'enzima che trasforma l'angiotensina I in angiotensina II, mentre gli ARB agiscono bloccando il recettore dell'angiotensina II, offrendo peraltro il vantaggio di minori effetti collaterali rispetto agli ACE-I, in particolare la tosse.

Daiichi Sankyo continua il proprio impegno nell'ipertensione e nello sviluppo dell'olmesartan. Lo studio SEVITENSION si è concentrato proprio sulla valutazione della combinazione fissa olmesartan/amlodipina.

Lo studio SEVITENSION ha analizzato la combinazione di 40 mg di
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Online Course Helps Employers Comply with OSHA’s Dec. 1, 2013, GHS Training Deadline
2. MedZilla.com Launches New Site Design for 2013, Slick New Interface Impresses
3. VIASPACE Chairman and CEO Attend EUEC 2013, Giant King Grass Prominently Featured in Convention Exhibit Hall
4. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
5. Retraction of Press Release Dated March 7, 2013, Regarding Recipient of Alumni Award from Johns Hopkins University
6. CANVUS Design Studio Specializes in Graphic Design and Commercials
7. Accelrys Materials Studio Release 6.1 Speeds Innovation with Enterprise Capabilities
8. Temple Run Gamers Have a New IOS Game To Play, Dream Bot Studios Explains
9. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
10. Winding River Productions Announces High-End Studio Enhancements Including SCORM-Compliant e-Learning Media Development and On-Location Data and Media Capture Platforms
11. Il Ministero della sanità canadese ha concesso le indicazioni sulla salute rivendicate da cinque formulazioni probiotiche di Lallemand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , September 2, 2014 Persistence ... Membrane Technology in Pharmaceutical, Biopharma and Life Sciences: ... by 2019" the global membrane technology market for pharmaceutical, biopharma and ... 2014 and is expected to grow at a CAGR ... estimated value of USD 10,886.0 million in 2019. ...
(Date:9/2/2014)... Myriant Corporation, a global renewable chemicals ... agreement with Azelis Group, a specialty chemicals distribution ... in the Nordics, Benelux, France, Iberia, Italy, the ... industrial and base chemicals markets. , “As a ... chemical portfolio with extensive distribution networks providing Myriant ...
(Date:9/2/2014)... , Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... developing engineered monoclonal antibodies for the treatment of ... today announced the appointment of Debra Zack ... the appointment of Lloyd Rowland , senior ... "Debra,s expertise in biologics clinical ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... orders consist of three large odour control systems for waste ... "These orders are consistent with the market resurgence in ... , President and CEO. "After a difficult period of restraint ... beginning to see sales growth. Our lower cost structure, technology ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... that it,has received the European CE Mark (Conformite Europeene) ... CE Mark certifies,that the product has met EU health, ... Granted in the Netherlands, the,registration will allow the system ... countries around the world that recognize the CE Mark. ...
... Calif., Oct. 29 Cliniqa Corporation (San,Marcos, ... is pleased to,announce the acquisition of the ... Diego, CA), a wholly owned subsidiary of ... manufacturer of clinical,diagnostic products focusing on clinical ...
... to Focus on Sales Growth and Product ... BioLife Solutions,Inc. (OTC Bulletin Board: BLFS), a ... and cryopreservation media products for,cells, tissues, and ... product,manufacturing, warehousing, and customer order fulfillment to ...
Cached Biology Technology:Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening 2Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 3
(Date:9/2/2014)... most ideal source of nutrition for infants and ... the evolution and civilizations of human beings. Unlike ... number of bacterial species, including some opportunistic pathogens ... to scientists and physicians. , Indeed, the existence ... result of co-evolutionary and co-adaptive interactions between the ...
(Date:9/2/2014)... integrity? Tell the truth; everyone has a tipping point. We ... lie if the benefit is great enough. Now, scientists have ... that decision. , The result was published online this ... prefer to be honest, even if lying is beneficial," said ... at the Virginia Tech Carilion Research Institute , where ...
(Date:9/2/2014)... propensity for eating anything, including each other, camel crickets ... North Carolina State University finds that non-native camel cricket ... States. , "The good news is that camel crickets ... humans," says Dr. Mary Jane Epps, a postdoctoral researcher ... about the research. , The research stems from a ...
Breaking Biology News(10 mins):Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Researchers find Asian camel crickets now common in US homes 2
... the triangle depicting how many servings of each food ... knows about MyPlate - the circle showing what a healthy ... United States Department of Agriculture (USDA) to help American consumers ... icon that prompts us to think about what,s on our ...
... gene therapy holds promise for the treatment of devastating genetic ... have been unclear. In a study online December 26th ... by Cell Press, researchers evaluated a patient with a genetic ... after he had undergone a gene therapy procedure as part ...
... neurodegenerative disorders, and drugs without significant side effects ... Institute of Synergon Consulting in Romania, led by ... is a transcription co-activator required for consolidation of ... same time involved in DNA replication and repair, ...
Cached Biology News:Who is using MyPlate? 2Gene therapy for human skin disease produces long-term benefits 2